linsitinib

Overview

Linsitinib (OSI-906) is an orally available, selective dual inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (INSR) tyrosine kinases. It was evaluated in phase II/III trials in adrenocortical carcinoma and Ewing sarcoma, where IGF-1R signaling is an established driver. It targets the IGF pathway that is implicated in multiple sarcoma subtypes.

Evidence in the corpus

• Linsitinib is among the compounds included in the sarcoma PDTO functional precision-medicine screen of 92 specimens; it is listed in the drugs screened across the UCLA sarcoma PDTO platform and appears in the drug-sensitivity landscape reported for diverse sarcoma histologies PMID:39305899.

Resistance mechanisms

• Not directly characterized in the corpus.

Cancer types (linked)

• Sarcoma (various histologies — included in PDTO functional screen panel)

Sources

• PMID:39305899 — Al Shihabi et al. 2024, Cell Stem Cell. Sarcoma PDTO functional precision-medicine screen; linsitinib included in drug library.

This page was processed by entity-page-writer on 2026-05-01.